RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Clinical trials for RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM trials appear
Sign up with your email to follow new studies for RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare cancers: targeted drug selpercatinib tested in phase 2 trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…
Matched conditions: RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with tough cancers: targeted drug attacks gene flaw
Disease control OngoingThis study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…
Matched conditions: RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC